These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

676 related items for PubMed ID: 16961157

  • 1. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
    Klotz U.
    Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
    [Abstract] [Full Text] [Related]

  • 2. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
    Zhao F, Wang J, Yang Y, Wang X, Shi R, Xu Z, Huang Z, Zhang G.
    Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419
    [Abstract] [Full Text] [Related]

  • 3. CYP2C19 polymorphism and proton pump inhibitors.
    Klotz U, Schwab M, Treiber G.
    Basic Clin Pharmacol Toxicol; 2004 Jul; 95(1):2-8. PubMed ID: 15245569
    [Abstract] [Full Text] [Related]

  • 4. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.
    Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH.
    Am J Gastroenterol; 2006 Jul; 101(7):1467-75. PubMed ID: 16863547
    [Abstract] [Full Text] [Related]

  • 5. Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans.
    Hu YM, Mei Q, Xu XH, Hu XP, Hu NZ, Xu JM.
    World J Gastroenterol; 2006 Aug 07; 12(29):4750-3. PubMed ID: 16937451
    [Abstract] [Full Text] [Related]

  • 6. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects.
    Hu YM, Xu JM, Mei Q, Xu XH, Xu SY.
    Acta Pharmacol Sin; 2005 Mar 07; 26(3):384-8. PubMed ID: 15715938
    [Abstract] [Full Text] [Related]

  • 7. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
    Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T.
    Drug Metab Pharmacokinet; 2005 Jun 07; 20(3):153-67. PubMed ID: 15988117
    [Abstract] [Full Text] [Related]

  • 8. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data.
    Schwab M, Klotz U, Hofmann U, Schaeffeler E, Leodolter A, Malfertheiner P, Treiber G.
    Clin Pharmacol Ther; 2005 Dec 07; 78(6):627-34. PubMed ID: 16338278
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
    Sahara S, Sugimoto M, Uotani T, Ichikawa H, Yamade M, Iwaizumi M, Yamada T, Osawa S, Sugimoto K, Umemura K, Miyajima H, Furuta T.
    Aliment Pharmacol Ther; 2013 Nov 07; 38(9):1129-37. PubMed ID: 24099474
    [Abstract] [Full Text] [Related]

  • 11. Pharmacogenomics of proton pump inhibitors.
    Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T.
    Pharmacogenomics; 2004 Mar 07; 5(2):181-202. PubMed ID: 15016609
    [Abstract] [Full Text] [Related]

  • 12. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
    Adachi K, Katsube T, Kawamura A, Takashima T, Yuki M, Amano K, Ishihara S, Fukuda R, Watanabe M, Kinoshita Y.
    Aliment Pharmacol Ther; 2000 Oct 07; 14(10):1259-66. PubMed ID: 11012469
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism.
    Ieiri I, Kishimoto Y, Okochi H, Momiyama K, Morita T, Kitano M, Morisawa T, Fukushima Y, Nakagawa K, Hasegawa J, Otsubo K, Ishizaki T.
    Eur J Clin Pharmacol; 2001 Sep 07; 57(6-7):485-92. PubMed ID: 11699613
    [Abstract] [Full Text] [Related]

  • 14. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
    Saitoh T, Fukushima Y, Otsuka H, Hirakawa J, Mori H, Asano T, Ishikawa T, Katsube T, Ogawa K, Ohkawa S.
    Aliment Pharmacol Ther; 2002 Oct 07; 16(10):1811-7. PubMed ID: 12269976
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.
    Qiao HL, Hu YR, Tian X, Jia LJ, Gao N, Zhang LR, Guo YZ.
    Eur J Clin Pharmacol; 2006 Feb 07; 62(2):107-12. PubMed ID: 16402242
    [Abstract] [Full Text] [Related]

  • 16. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
    Ogilvie BW, Yerino P, Kazmi F, Buckley DB, Rostami-Hodjegan A, Paris BL, Toren P, Parkinson A.
    Drug Metab Dispos; 2011 Nov 07; 39(11):2020-33. PubMed ID: 21795468
    [Abstract] [Full Text] [Related]

  • 17. Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians.
    Hunfeld NG, Mathot RA, Touw DJ, van Schaik RH, Mulder PG, Franck PF, Kuipers EJ, Geus WP.
    Br J Clin Pharmacol; 2008 May 07; 65(5):752-60. PubMed ID: 18241283
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
    Zvyaga T, Chang SY, Chen C, Yang Z, Vuppugalla R, Hurley J, Thorndike D, Wagner A, Chimalakonda A, Rodrigues AD.
    Drug Metab Dispos; 2012 Sep 07; 40(9):1698-711. PubMed ID: 22648560
    [Abstract] [Full Text] [Related]

  • 19. [The effect of proton pump inhibitor on intragastric acidity and it relation to S-mephenytoin hydroxylase genetic polymorphism].
    Wang H, Nie YQ, Dai SJ, She QZ, Li YY.
    Zhonghua Nei Ke Za Zhi; 2003 Nov 07; 42(11):777-80. PubMed ID: 14636465
    [Abstract] [Full Text] [Related]

  • 20. Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole.
    Ormeci A, Emrence Z, Baran B, Gokturk S, Soyer OM, Evirgen S, Akyuz F, Karaca C, Besisik F, Kaymakoglu S, Ustek D, Demir K.
    Eur Rev Med Pharmacol Sci; 2016 Mar 07; 20(5):879-85. PubMed ID: 27010145
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.